Bing

SEARCH HISTORY

Myriad Genetics Inc:Expects Q4 2015 total revenues of $187 to $189 million and adjusted diluted earnings per share of $0.40 to $0.42 (GAAP diluted EPS of $0.28 to $0.30).Revises FY 2015 financial guidance and expects total revenues of $720 to $722 …
Reuters · 5/5/2015
CHICAGO, March 31, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, GWPH, AA, MYGN and COH. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
Market Watch · 3/31/2015
John Tannahill Henderson BSc. M.B, Ch.B, MRCP, M.D., Ph.D. 49 Relationships Myriad Genetics Inc. 70 Peter D. Meldrum Ph.D. 62 Relationships Myriad Genetics Inc. 67 Walter A. Gilbert Ph.D. 35 Relationships Myriad Genetics Inc. 82
Bloomberg · 2/3/2015
More from Bing News
It’s an illness that fortunately only affects 1% of the global population . . . but for those diagnosed, schizophrenia is one of the most mentally paralyzing, debilitating brain disorders. It can be dangerous, too, with some victims becoming ...
Trefis · 4/9/2014
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Smallcap-Investors.com. BOCA RATON, FL--(Marketwire - February 2, 2010) - TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of …
marketwired.com · 2/2/2010
Editor’s Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Acorda Therapeutics Inc (NASDAQ:ACOR), Myriad Genetics, Inc. (NASDAQ:MYGN ... Amgen Stock Rating Reaffirmed by …
INSIDER MONKEY · 4/15/2013
The genetics industry is in for a shake-up following Thursday's U.S. Supreme Court ruling that human genes can't be patented ... The company at the center of the case, Myriad Genetics (MYGN), was attempting to retain exclusive rights to find, isolate ...
CNN Money · ByJose Pagliery · 6/13/2013
Meanwhile, Myriad Genetics /quotes/zigman/58124 /quotes/nls/mygn MYGN was one of the few that did manage to buck the tide, rising nearly 2% after notes from other firms in the field concluded that synthetic DNA could be patentable. The U.S. Supreme …
Market Watch Commentary · ByRuss Britt · 6/20/2013
SALT LAKE CITY, May 15, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data for its Prolaris test at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La.
istock Analyst · 5/15/2015
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological …
Stockhouse · 5/7/2015